Trial Profile
Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs BQ 788 (Primary)
- Indications Malignant melanoma
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors MelCure
- 22 May 2015 Status changed from not stated to discontinued.
- 15 May 2015 New trial record